Ac2-26 acetate, the bioactive N-terminal fragment of annexin A1, mitigates acute lung injury in ischemia-reperfusion models by downregulating AnxA1 expression and suppressing NF-κB and MAPK pathway activation. This peptide is a valuable research tool for studying inflammatory pathways in both in vivo and in vitro experimental systems.